

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claims 1-4. (Canceled)

Claim 5. (Previously presented). The peptide according to claim 16 which has the formula:
NH₂-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-Phe-OH (SEQ ID NO. 6),
NH₂-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-OH (SEQ ID NO. 7),
NH₂-Leu-Arg-Ile-Leu-Leu-Leu-Gly-Val-OH (SEQ ID NO. 8),
NH₂-Leu-Gly-Ile-Leu-Leu-Leu-Lys-Val-OH (SEQ ID NO. 9),
NH₂-Ile-Leu-Leu-Gly-Lys-Ala-Thr-Leu-Tyr-OH (SEQ ID NO. 10),
NH₂-Met-Gly-Leu-Arg-Ile-Leu-Leu-Leu-OH (SEQ ID NO. 11), or
NH₂-Leu-Leu-Met-Thr-Leu-Arg-Leu-Trp-Ser-Ser-COOH (SEQ ID NO. 12).

Claim 6. (Canceled)

Claim 7. (Previously presented) A peptide which inhibits TCR function, wherein the peptide has the formula

NH₂-Ile-Ile-Val-Thr-Asp-Val-Ile-Ala-Thr-Leu-OH (SEQ ID NO. 13),
NH₂-Ile-Val-Ile-Val-Asp-Ile-Cys-Ile-Thr-OH (SEQ ID NO. 14), or
NH₂-Phe-Leu-Phe-Ala-Glu-Ile-Val-Ser-Ile-OH (SEQ ID NO. 15).

Claim 8. (Previously Presented) A peptide which inhibits TCR function, wherein the peptide is derived from the TCR- α intracellular chain and comprises the formula:

NH₂-Ala-Gly-Phe-Asn-Leu-Leu-Met-Thr-COOH (SEQ ID NO. 16).

Claims 9-11. (Canceled)

Claim 12. (Previously Presented) A peptide which inhibits T-Cell antigen receptor function wherein the peptide has the formula:

NH₂-Tyr-Gly-Arg-Ala-Asp-Cys-Gly-Ile-Thr-Ser-OH (SEQ ID NO. 17), or
NH₂-Trp-Gly-Arg-Ala-Asp-Cys-Gly-Ile-Thr-Ser-OH (SEQ ID NO. 18), or
NH₂-Tyr-Gly-Arg-Ala-Asp-Cys-Ile-Thr-Ser-OH (SEQ ID NO. 19), or

NH2-Ser-Ser-Asp-Val-Pro-Cys-Asp-Ala-Thr-Leu-Thr-OH (SEQ ID NO. 20).

- Claim 13. (Currently amended) A therapeutic composition ~~active against disorders in which T-cells are involved or recruited~~ comprising a peptide as claimed in claim 16, and a pharmaceutically acceptable carrier.
- Claim 14. (Currently amended) A method of treating a subject suffering from a ~~disorder in which T-cells are involved or recruited~~ condition selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, psoriasis, inflammatory conditions, myositis, and ankylosing spondylitis, the method ~~including~~ comprising the step of administering to the subject a therapeutically an effective amount of ~~the a~~ composition as claimed in claim 13 to the subject.
- Claim 15. (Canceled)
- Claim 16. (Previously presented) A peptide that inhibits T-cell antigen receptor (TCR function, which has a formula selected from the group consisting of formula
- NH2-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-Phe-OH (SEQ ID NO. 6),
NH2-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-OH (SEQ ID NO. 7),
NH2-Leu-Arg-Ile-Leu-Leu-Leu-Gly-Val-OH (SEQ ID NO. 8),
NH2-Leu-Gly-Ile-Leu-Leu-Leu-Lys-Val-OH (SEQ ID NO. 9),
NH2-Ile-Leu-Leu-Gly-Lys-Ala-Thr-Leu-Tyr-OH (SEQ ID NO. 10),
NH2-Met-Gly-Leu-Arg-Ile-Leu-Leu-Leu-OH (SEQ ID NO. 11),
NH2-Leu-Leu-Met-Thr-Leu-Arg-Leu-Trp-Ser-Ser-COOH (SEQ ID NO. 12)
NH2-Ile-Ile-Val-Thr-Asp-Val-Ile-Ala-Thr-Leu-OH (SEQ ID NO. 13)
NH2-Ile-Val-Ile-Val-Asp-Ile-Cys-Ile-Thr-OH (SEQ ID NO. 14),
NH2-Phe-Leu-Phe-Ala-Glu-Ile-Val-Ser-Ile-OH (SEQ ID NO. 15)
NH2-Ala-Gly-Phe-Asn-Leu-Leu-Met-Thr-COOH (SEQ ID NO. 16).
- Claim 17. (New) A method according to claim 14, in which the condition is rheumatoid arthritis or psoriasis.